COMPASS Pathways
COMPASS Pathways is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor investor investor investor | €0.0 | round |
| N/A | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor investor investor | €0.0 | round | |
* | N/A | $150m | Post IPO Equity |
| Total Funding | 000k | ||
| EUR | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | - | - | - | - | (3396 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | - | - | - | - | (3653 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Equity research estimates
Related Content
COMPASS Pathways plc is a mental health care company focused on developing innovative treatments for mental health disorders, specifically targeting treatment-resistant depression. The company operates in the pharmaceutical and biotechnology market, leveraging its proprietary psilocybin therapy, COMP360, to address unmet medical needs. COMPASS Pathways serves patients who have not responded to traditional antidepressant therapies, providing a novel approach through its clinical trials and research initiatives. The business model is centered around the development, clinical testing, and eventual commercialization of its psilocybin-based treatments. Revenue is generated through partnerships, licensing agreements, and future sales of approved therapies. The company has gained significant attention and investment, highlighted by its successful $146.6 million IPO and participation in major industry conferences.
Keywords: psilocybin therapy, mental health, treatment-resistant depression, clinical trials, biotechnology, pharmaceutical, COMP360, innovative treatments, IPO, research initiatives.